Patents by Inventor Virginia L. Pulito

Virginia L. Pulito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDR-GRAFTED ANTI-TISSUE FACTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20100298544
    Abstract: The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Application
    Filed: June 10, 2010
    Publication date: November 25, 2010
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-grafted anti-tissue factor antibodies and methods of use thereof
    Patent number: 7777018
    Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: August 17, 2010
    Assignee: Centocor, Inc.
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-grafted anti-tissue factor antibodies and methods of uses there of
    Patent number: 7544790
    Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: June 9, 2009
    Assignee: Centocor, Inc.
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds
    Patent number: 7517885
    Abstract: The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: April 14, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Virginia L. Pulito, Shengjian Li
  • Piperazinyl substituted cyclohexane-1,4-diamines
    Patent number: 7482348
    Abstract: The present invention relates to piperazine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: January 27, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Shengjian Li, Peter J. Connolly, Virginia L. Pulito, Jingchun Liu, Steven A. Middleton
  • Piperidinyl substituted cyclohexane-1,4-diamines
    Patent number: 7470711
    Abstract: The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: December 30, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Shengjian Li, Peter J. Connolly, Virginia L. Pulito, Jingchun Liu, Steven A. Middleton
  • Substituted isoindole-1,3-diones
    Patent number: 7459557
    Abstract: The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: December 2, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Virginia L. Pulito, Shengjian Li
  • CDR-Grafted Anti-Tissue Factor Antibodies and Methods of Use Thereof
    Publication number: 20080226628
    Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Application
    Filed: October 29, 2007
    Publication date: September 18, 2008
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-grafted anti-tissue factor antibodies and methods of use thereof
    Patent number: 7235380
    Abstract: The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: June 26, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
  • CDR-GRAFTED ANTIBODIES
    Publication number: 20020099179
    Abstract: There are disclosed: a CDR-grafted antibody having at least one chain wherein the framework regions are predominantly derived from a first antibody (acceptor) and at least one CDR is derived from a second antibody (donor), the CDR-grafted antibody being capable of binding to the CD4 antigen; processes for its production; nucleotide sequences for use in its production; compositions containing
    Type: Application
    Filed: January 13, 1999
    Publication date: July 25, 2002
    Inventors: LINDA K. JOLLIFFE, ROBERT A. ZIYIN, VIRGINIA L. PULITO, JOHN R. ADAIR, DILJEET S. ATHWAL